GLP-1 Use Among Americans Reaches New Peak
Recent polling data indicates that patient utilization of GLP-1 medications has reached its highest historical level. Eleven percent of…
-
-
Single Hepatic Failure Report Linked to Eli Lilly’s Foundayo Triggers Market Volatility, Analysts Urge Caution Over Interpretation
A single case of hepatic failure associated with the medication Foundayo recently appeared within federal reporting databases. This specific…
-
US Prescription Drug Spending Approaches $1 Trillion, Fueled by GLP-1 Market Surge
Spending on prescription drugs just hit $915 billion. Compared to the previous year, this number shows a rise of…
-
GLP-1 Drug Response DNA Tests Expected in 2026
PrecisionLife and Ovation.io have recently concluded a commercialization deal for genetic response tests related to GLP-1 receptor agonists. The…
-
What Comes After GLP-1
The pharmaceutical landscape for metabolic health has shifted dramatically since GLP-1 receptor agonists first hit the scene. These medications…
-
Oral vs Injectable Bioavailability
Choosing a new medication is a massive step toward taking back control of your health and your future. For…
-
Oral Semaglutide Offers New Cardiac Hope for Diabetes Patients
Oral semaglutide provides vital heart protection for patients managing type 2 diabetes and heart failure. A recent analysis shows…
-
GLP-1 Pills Under Medicaid: Coverage Dynamics and Access Considerations
The medical community is seeing a major shift as more people choose daily tablets to manage their metabolic health….
